AR035137A1 - Composicion farmaceutica para inhibir metastasis o prevenir recurrencia de tumor maligno - Google Patents
Composicion farmaceutica para inhibir metastasis o prevenir recurrencia de tumor malignoInfo
- Publication number
- AR035137A1 AR035137A1 ARP020103077A ARP020103077A AR035137A1 AR 035137 A1 AR035137 A1 AR 035137A1 AR P020103077 A ARP020103077 A AR P020103077A AR P020103077 A ARP020103077 A AR P020103077A AR 035137 A1 AR035137 A1 AR 035137A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- formula
- active ingredient
- pharmaceutical composition
- possesses
- Prior art date
Links
- 206010027476 Metastases Diseases 0.000 title abstract 2
- 230000009401 metastasis Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000002947 alkylene group Chemical group 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 230000000259 anti-tumor effect Effects 0.000 abstract 2
- 150000004676 glycans Chemical class 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 229920001282 polysaccharide Polymers 0.000 abstract 2
- 239000005017 polysaccharide Substances 0.000 abstract 2
- 125000003277 amino group Chemical group 0.000 abstract 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Una composición farmacéutica para inhibir metástasis o prevenir la recurrencia de un tumor maligno, que comprende como ingrediente activo un derivado de polisacárido que comprende un polisacárido que posee un grupo carboxilo unido a un ingrediente activo que posee una actividad antitumor por medio de un aminoácido o un péptido de 2 a 8 aminoácidos que son iguales o diferentes, o una sal del mismo. Preferentemente, el ingrediente activo que posee una actividad antitumor es un derivado de camptotecina de la fórmula (1) en donde R1 es un grupo alquilo inferior sustituido o sin sustituir; X1 es un grupo de la fórmula: -NHR2 (R2 es un átomo de hidrógeno o un grupo alquilo inferior) y Alk es un grupo alquileno C1-6 de cadena lineal o cadena ramificada que opcionalmente posee un átomo de oxígeno en la cadena del mismo, o un compuesto de la fórmula (2) en donde dos grupos de R2 a R6 que son adyacentes entre sí se combinan para formar un grupo alquileno inferior, y uno de los átomos del carbono de dicho grupo alquileno inferior es sustituido por un grupo amino, y los tres grupos de R2 a R6 restantes son un átomo de hidrógeno, un grupo alquilo inferior o un átomo de halógeno.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001249717 | 2001-08-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035137A1 true AR035137A1 (es) | 2004-04-14 |
Family
ID=19078678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020103077A AR035137A1 (es) | 2001-08-21 | 2002-08-15 | Composicion farmaceutica para inhibir metastasis o prevenir recurrencia de tumor maligno |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1418947A1 (es) |
| KR (1) | KR20040027972A (es) |
| CN (1) | CN100372570C (es) |
| AR (1) | AR035137A1 (es) |
| AU (1) | AU2002328093B2 (es) |
| BR (1) | BR0212036A (es) |
| CA (1) | CA2457056C (es) |
| HU (1) | HUP0401351A3 (es) |
| IL (1) | IL160148A0 (es) |
| MX (1) | MXPA04001599A (es) |
| NO (1) | NO20041194L (es) |
| NZ (1) | NZ530947A (es) |
| PL (1) | PL368319A1 (es) |
| RU (1) | RU2275913C2 (es) |
| TW (1) | TWI313609B (es) |
| UA (1) | UA75450C2 (es) |
| WO (1) | WO2003015826A1 (es) |
| ZA (1) | ZA200400917B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200306314A (en) * | 2002-04-16 | 2003-11-16 | Tanabe Seiyaku Co | Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation |
| RU2283848C1 (ru) * | 2005-06-16 | 2006-09-20 | Институт нефтехимии и катализа РАН Республика Башкортостан | Способ получения конъюгатов альгиновой кислоты |
| FR2914305B1 (fr) | 2007-03-29 | 2009-07-03 | Proteins & Peptides Man | Dextran fonctionnalise par des amino-acides hydrophobes. |
| RU2320334C1 (ru) * | 2006-08-07 | 2008-03-27 | Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО НижГМА Росздрава) | Средство для ингибирования роста опухоли и способ ингибирования роста опухоли в эксперименте |
| RU2359975C2 (ru) * | 2007-04-04 | 2009-06-27 | Институт нефтехимии и катализа РАН | Способ получения модифицированных арабиногалактанов |
| CN104328050B (zh) | 2008-07-16 | 2017-12-15 | 儿童医疗中心有限公司 | 具有微通道的器官模仿装置及其使用和制造方法 |
| RU2631807C2 (ru) | 2011-06-02 | 2017-09-26 | Президент Энд Феллоуз Ов Харвард Колледж | Способы и применение систем культуры ткани ex vivo |
| PL221351B1 (pl) | 2012-03-14 | 2016-03-31 | Politechnika Warszawska | Sposób otrzymywania nanocząstek polisacharydowych |
| CN115960111A (zh) * | 2012-10-11 | 2023-04-14 | 第一三共株式会社 | 抗体－药物偶联物 |
| WO2014061277A1 (ja) | 2012-10-19 | 2014-04-24 | 第一三共株式会社 | 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート |
| PL4212552T3 (pl) | 2014-01-31 | 2025-03-17 | Daiichi Sankyo Company, Limited | Koniugat przeciwciało anty-her2-lek |
| TWI718144B (zh) | 2015-05-04 | 2021-02-11 | 美商輝瑞股份有限公司 | Ｂ型鏈球菌多醣－蛋白質軛合物、製造軛合物之方法、含軛合物之免疫原性組成物、及其用途 |
| IL290959B2 (en) | 2015-06-29 | 2023-04-01 | Daiichi Sankyo Co Ltd | Preparations containing antibody-drug conjugates and methods for their production |
| TW202508642A (zh) | 2016-12-12 | 2025-03-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物與免疫檢查點抑制劑之組合、以及醫藥組成物之用途 |
| TWI780104B (zh) | 2017-01-17 | 2022-10-11 | 日商第一三共股份有限公司 | 抗ｇｐｒ２０抗體及抗ｇｐｒ２０抗體-藥物結合物、以及其製造方法及用途 |
| TW202530219A (zh) | 2017-05-15 | 2025-08-01 | 日商第一三共股份有限公司 | 抗體－藥物結合物之製造方法 |
| CN117838881A (zh) | 2017-08-31 | 2024-04-09 | 第一三共株式会社 | 制备抗体-药物缀合物的新方法 |
| EP3677589B1 (en) | 2017-08-31 | 2025-11-26 | Daiichi Sankyo Company, Limited | Improved method for producing antibody-drug conjugate |
| BR112020023373A2 (pt) | 2018-05-18 | 2021-02-09 | Daiichi Sankyo Company, Limited | conjugado, composição, e, uso de um conjugado ou de uma composição |
| TWI846717B (zh) | 2018-07-27 | 2024-07-01 | 日商第一三共股份有限公司 | 辨識抗體-藥物結合物之藥物部位的蛋白質 |
| SG11202100947SA (en) | 2018-07-31 | 2021-03-30 | Daiichi Sankyo Co Ltd | Treatment of metastatic brain tumor by administration of antibody-drug conjugate |
| CN109481691A (zh) * | 2018-11-20 | 2019-03-19 | 珠海天香苑生物科技发展股份有限公司 | 吉西他滨-羧甲基多糖共轭物、制备方法及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0640622B1 (en) * | 1993-02-26 | 2000-08-09 | Drug Delivery System Institute, Ltd. | Polysaccharide derivative and drug carrier |
| SG50747A1 (en) * | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
| CA2192725C (en) * | 1995-12-28 | 2004-04-20 | Kenji Tsujihara | Camptothecin derivatives |
| WO1997038727A1 (en) * | 1996-04-15 | 1997-10-23 | Asahi Kasei Kogyo Kabushiki Kaisha | Medicament composite |
| TW527183B (en) * | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
| CN1058038C (zh) * | 1996-12-31 | 2000-11-01 | 中国科学院感光化学研究所 | 低收缩性光固化涂层材料及其制法和用途 |
| EP1080732A4 (en) * | 1998-05-22 | 2004-08-25 | Daiichi Seiyaku Co | DRUG COMPOSITION |
-
2002
- 2002-08-14 TW TW091118260A patent/TWI313609B/zh not_active IP Right Cessation
- 2002-08-15 AR ARP020103077A patent/AR035137A1/es unknown
- 2002-08-16 NZ NZ530947A patent/NZ530947A/en not_active IP Right Cessation
- 2002-08-16 BR BR0212036-4A patent/BR0212036A/pt not_active IP Right Cessation
- 2002-08-16 IL IL16014802A patent/IL160148A0/xx unknown
- 2002-08-16 RU RU2004108141/15A patent/RU2275913C2/ru not_active IP Right Cessation
- 2002-08-16 MX MXPA04001599A patent/MXPA04001599A/es unknown
- 2002-08-16 AU AU2002328093A patent/AU2002328093B2/en not_active Ceased
- 2002-08-16 KR KR10-2004-7002566A patent/KR20040027972A/ko not_active Ceased
- 2002-08-16 HU HU0401351A patent/HUP0401351A3/hu unknown
- 2002-08-16 EP EP02762786A patent/EP1418947A1/en not_active Withdrawn
- 2002-08-16 UA UA2004032071A patent/UA75450C2/uk unknown
- 2002-08-16 CN CNB028163176A patent/CN100372570C/zh not_active Expired - Fee Related
- 2002-08-16 WO PCT/JP2002/008309 patent/WO2003015826A1/en not_active Ceased
- 2002-08-16 PL PL02368319A patent/PL368319A1/xx not_active Application Discontinuation
- 2002-08-16 CA CA002457056A patent/CA2457056C/en not_active Expired - Fee Related
-
2004
- 2004-02-04 ZA ZA200400917A patent/ZA200400917B/en unknown
- 2004-03-19 NO NO20041194A patent/NO20041194L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200400917B (en) | 2004-08-25 |
| KR20040027972A (ko) | 2004-04-01 |
| UA75450C2 (en) | 2006-04-17 |
| RU2275913C2 (ru) | 2006-05-10 |
| WO2003015826A1 (en) | 2003-02-27 |
| BR0212036A (pt) | 2004-08-17 |
| PL368319A1 (en) | 2005-03-21 |
| IL160148A0 (en) | 2004-07-25 |
| CA2457056A1 (en) | 2003-02-27 |
| CA2457056C (en) | 2008-07-22 |
| AU2002328093B2 (en) | 2005-05-05 |
| CN100372570C (zh) | 2008-03-05 |
| HUP0401351A2 (hu) | 2004-12-28 |
| RU2004108141A (ru) | 2005-04-20 |
| NO20041194L (no) | 2004-03-19 |
| EP1418947A1 (en) | 2004-05-19 |
| HUP0401351A3 (en) | 2011-02-28 |
| TWI313609B (en) | 2009-08-21 |
| CN1545423A (zh) | 2004-11-10 |
| NZ530947A (en) | 2006-04-28 |
| MXPA04001599A (es) | 2004-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035137A1 (es) | Composicion farmaceutica para inhibir metastasis o prevenir recurrencia de tumor maligno | |
| TR200402656T4 (tr) | Antikanser ajanları olarak faydalı tiyofen türevleri | |
| CY1109457T1 (el) | Παραγωγο aminoαλκοολης ή παραγωγο φωσφονικου οξεος και φαρμακευτικη συνθεση που τα περιεχει | |
| BR0315547A (pt) | Derivados de quinolina como antagonistas de crth2 | |
| UA116616C2 (uk) | Інгібітори hcv серинової протеази, отримані з макроциклічного проліну | |
| EA201170607A1 (ru) | Акриламидопроизводные, применимые как ингибиторы перехода митохондриальной проницаемости | |
| EP1481965A4 (en) | AROMATIC AMINO ACID DERIVATIVES AND MEDICAL COMPOSITIONS | |
| TR200103186T2 (tr) | MEK enzimlerinin inhibitörleri olarak kinolin türevleri | |
| TR200103390T2 (tr) | Proteaz inhibitörleri olan yeni bileşikler ve terkipler. | |
| AR035365A1 (es) | Compuesto peptidico que comprende un centro inhibidor de la metionina aminopeptidasa 2 (metap-2) y su uso para preparar un medicamento | |
| EA200801611A1 (ru) | Противораковые комбинации | |
| CY1106522T1 (el) | Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο | |
| MX2011012356A (es) | Compuesto anticanceroso y composicion farmaceutica que lo contiene. | |
| CO5631443A2 (es) | Derivados de 7-aril-3,9-diazabiciclo (3.3.1) non-6-eno y su uso como inhibidores de renina en el tratamiento de enfermedades de hipertension, cardiovasculares o renales | |
| ATE404536T1 (de) | Substituierte chinolinderivate als inhibitoren von mitotischem kinesin | |
| MX2010008109A (es) | Tripéptidos difluorizados como inhibidores de proteasa de serina de virus de hepatitis c (hcv). | |
| CO6270285A2 (es) | Derivados de 4-[(4-amino-1, 3, 5-triazin-2-il)amino]-n-arilmetilcicloalquilcarboxamida | |
| GEP20125548B (en) | New dihidroindolone compounds, a process for its preparation and pharmaceutical compositions containing them | |
| EP3558317A1 (en) | Combination chemotherapies | |
| AR024918A1 (es) | Derivados de ciclobuteno, su preparacion y sus usos terapeuticos. | |
| EA200700976A1 (ru) | Соединения в виде молекул-конъюгатов, обладающих повышенной активностью в отношении включения клеткой | |
| UY27930A1 (es) | Derivados de tiazol | |
| UY27975A1 (es) | Derivados de indolilo | |
| AR059113A1 (es) | Composicion para administracion topica | |
| BRPI0506889A (pt) | derivados de benzimidazol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |